A Phase IV Open Label Randomised Multi Centric Prospective Parallel Active Controlled Comparative Clinical trial to assess the Efficacy and Safety of Fixed Dose Combination of Diclofenac Sodium IP 50 mg as enteric coated granules Paracetamol IP 325 mg and Chlorzoxazone USP 250 mg uncoated tablet LOBAK of Geno Pharmaceuticals Private Limited compared to Fixed Dose Combination of Diclofenac sodium IP 50 mg as enteric coated granules and Paracetamol IP 325 mg uncoated tablet DICLOMOL of Win Medicare Private Limited in patients with Acute Musculoskeletal Spasm - NIL
100 项与 Geno Pharmaceuticals Pvt Ltd. 相关的临床结果
0 项与 Geno Pharmaceuticals Pvt Ltd. 相关的专利(医药)
100 项与 Geno Pharmaceuticals Pvt Ltd. 相关的药物交易
100 项与 Geno Pharmaceuticals Pvt Ltd. 相关的转化医学